Nagendran Sukumar 4

4 · Taysha Gene Therapies, Inc. · Filed Jan 14, 2026

Insider Transaction Report

Form 4

Period: 2026-01-12

Taysha Gene Therapies, Inc.TSHA

Nagendran Sukumar

DirectorPresident and Head of R&D

Transactions

Exercise/Conversion
Common Stock
2026-01-12$0.70/sh+111,324$77,804→ 1,117,763 total
Exercise/Conversion
Common Stock
2026-01-12$1.71/sh+88,676$151,636→ 1,206,439 total
Sale
Common Stock
[F1][F2]
2026-01-12$4.71/sh−200,000$942,000→ 1,006,439 total
Award
Common Stock
[F3]
2026-01-12+427,000→ 1,433,439 total
Exercise/Conversion
Employee Stock Option (right to buy)
[F4]
2026-01-12−111,324→ 111,359 total
Exercise: $0.70Exp: 2033-12-14→ Common Stock (111,324 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
[F5]
2026-01-12−88,676→ 474,941 total
Exercise: $1.71Exp: 2034-01-02→ Common Stock (88,676 underlying)
Award
Employee Stock Option (right to buy)
[F6]
2026-01-12+274,000→ 274,000 total
Exercise: $4.86Exp: 2036-01-12→ Common Stock (274,000 underlying)

Footnotes (6)

[F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
[F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
[F4]The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
[F5]25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
[F6]25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Signature

/s/ Kamran Alam, Attorney-in-Fact|2026-01-14

Documents

1 file

4
form4-01142026_040101.xmlPrimary